PsiOxus lures two corporate VCs into £22m series B for oncolytic vaccine
This article was originally published in Scrip
Executive Summary
PsiOxus Therapeutics, a UK-based biotechnology company, has raised £22 million in a series B round in which existing investors Imperial Innovations and Invesco Perpetual each put in £5.5 million. The remaining £11 million was supplied by new investors SR One (GlaxoSmithKline's venture arm) and Lundbeckfond Ventures.